INBX
Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$109.35
+4.41%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$2.45
- Revenue estimate
- $1.9M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$2.34
- EPS estimate
- -$2.28
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -1.1%
- Revenue beats (12Q)
- 2
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$2.28 | -$2.34 | Miss -2.63% | — |
| May 14, 2026 | -$2.37 | -$2.15 | Beat 9.28% | — |
| Mar 19, 2026 | -$2.08 | -$2.11 | Miss -1.44% | — |
| Nov 14, 2025 | -$2.08 | -$2.28 | Miss -9.62% | — |
| Aug 13, 2025 | -$2.92 | -$1.85 | Beat 36.64% | $1.3M |
| May 14, 2025 | -$2.55 | -$2.80 | Miss -9.80% | — |
| Mar 17, 2025 | -$2.88 | -$3.09 | Miss -7.29% | $100.0K |
| Nov 14, 2024 | -$3.06 | -$2.84 | Beat 7.19% | — |
| Aug 13, 2024 | -$3.60 | $125 | Beat 3585.56% | $100.0K |
| Jun 3, 2024 | -$1.04 | -$1.44 | Miss -38.46% | — |
| Feb 28, 2024 | -$1.07 | -$1.73 | Miss -61.68% | $1.6M |
| Nov 9, 2023 | -$1.01 | -$1.10 | Miss -8.91% | $119.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026